<DOC>
	<DOCNO>NCT02021942</DOCNO>
	<brief_summary>This monocenter , single-arm , open label phase II trial evaluate effect SOM230 LAR adult patient inoperable primary thymoma thymoma metastasis ( Masaoka II-IVa ) . SOM230 LAR dosage 60 mg administer i.m . every 4 week . The purpose trial proof concept .</brief_summary>
	<brief_title>Efficacy Medical Treatment With SOM230 LAR Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma Reduce Tumor Size</brief_title>
	<detailed_description />
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Thymus Neoplasms</mesh_term>
	<criteria>Male female patient age â‰¥18 year Diagnosis thymoma assess biopsy and/or szintigraphy Inoperability thymoma locoregional metastasis . Inoperability define least adherence tumor neighbor organ , suspicious infiltrate neighbor organ local metastasis R0 resection expect /or local recurrence thymic tumor Tumor stage : Thymomas WHO base histological subtypes ( WHO A , AB , B1 , B2 , B3 ) ( Rosai , 1999 ; Travis 2004 ) Masaoka stage II IVa base histological examination resection specimens core biopsy . Patients without thymoma associate paraneoplastic syndrome . Performance status 0,1 , 2 ( ECOG ) Patients write informed consent participate study obtain Patients receive radiolabeled somatostatin analogue therapy within 6 month cytotoxic chemotherapy interferon therapy within 2 month prior record baseline symptom Patients undergone major surgery/surgical therapy cause within 1 month surgical therapy locoregional metastasis within last 3 month record baseline symptom Patients receive radiotherapy reason within last 4 week must recover side effect radiotherapy record baseline symptom Patients biochemically euthyroid Diabetic patient antidiabetic medication whose fast blood glucose poorly control indicated HbA1C &gt; 8 % Patients symptomatic cholelithiasis Patients congestive heart failure ( NYHA Class III IV ) , unstable angina , sustain ventricular tachycardia , ventricular fibrillation , clinically significant bradycardia , advanced heart block history acute myocardial infarction within six month precede enrollment Patients QT relate risk factor : QTcF screen &gt; 450 msec Patients QT relate risk factor : History syncope family history idiopathic sudden death Patients QT relate risk factor : Sudden clinically significant cardiac arrhythmia Patients QT relate risk factor : Risk factor Torsades de Pointes hypokalemia , hypomagnesemia , cardiac failure , clinically significant / symptomatic bradycardia , highgrade AV block Patients QT relate risk factor : Concomitant disease ( ) could prolong QT autonomic neuropathy ( cause diabetes Parkinson 's disease ) , HIV , cirrhosis , uncontrolled hypothyroidism cardiac failure Patients QT relate risk factor : Concomitant medication ( ) know increase QT interval Patients potassium &lt; 3.0 mmol/L study entry , magnesium &lt; 0.4 mmol/L study entry , calcium &lt; 1.75 mmol/L study entry , family history long QT syndrome , concomitant medication know prolong QT interval . If electrolyte abnormality correct prior study commencement , patient may become eligible trial . Patients liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis serum bilirubin &gt; 1.5 X ULN , serum albumin &lt; 0.67 X LLN , and/or ALT AST 2 X ULN patient without liver Confidential 20 Amended Clinical Study Protocol v01 / Track Changes Study No . CSOM230CIC01T metastases ALT AST 5X ULN patient document liver metastasis Patients additional active malignant disease within last five year ( exception basal cell carcinoma carcinoma situ cervix ) Patients presence active suspect acute chronic uncontrolled infection history immunocompromise , include positive HIV test result ( ELISA Western blot ) . A HIV test require ; however , previous medical history review Patients abnormal coagulation ( PT APTT elevate 30 % normal limit ) Patients WBC &lt; 2.5 X 109/L ; Hgb &lt; 10 g/dL ; PLT &lt; 100 X 109/L ( patient paraneoplastic pan , leuco , erythro thrombopenia include seem reason pan , leuco , erythro thrombopenia ) Known hypersensitivity somatostatin analogue component pasireotide octreotide LAR s.c. formulation Patients current prior medical condition may interfere conduct study evaluation result opinion investigator Female patient pregnant lactating , childbearing potential practicing medically acceptable method birth control . Female patient must use secure method contraception sexually active partner use condom . If oral contraception use , patient must practice method least two month prior enrollment must agree continue oral contraceptive throughout course study , three month study end . Male patient sexually active require use condom study three month afterwards precautionary measure ( available data suggest increase reproductive risk study drug ) . Female partner male patient use secondary barrier contraception . Patients currently part participate clinical investigation investigational drug within 1 month prior dose Patients history noncompliance medical regimen consider potentially unreliable able complete entire study Patient receive investigational agent within 28 day first day study drug dose Abnormal clinical laboratory value consider investigator clinically significant could affect interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>primary inoperable thymoma</keyword>
	<keyword>local recurrent thymoma</keyword>
	<keyword>reduction tumor size</keyword>
	<keyword>SOM230 LAR</keyword>
</DOC>